Lytix Biopharma is delighted to share our latest publication in “Trends in Cancer”
The publication is written together with our scientific collaborators at Cornell NY, USA.
In this review article, we discuss the challenge of cancer intra-tumoral heterogeneity and its association with therapy resistance and poor prognosis. Furthermore, we discuss how the molecular and immunological pathways engaged by oncolytic peptides combined with immune checkpoint inhibitors stands out as a promising therapeutic strategy for the treatment of intra-tumoral heterogeneity.
“Trends in Cancer” is a leading reviews journal covering advances in cancer research and oncology, published by Cell Press.